Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells.

Up-regulation of lipogenesis by androgen is one of the most characteristic metabolic features of LNCaP prostate cancer cells. The present study revealed that androgen increases glucose utilization for de novo lipogenesis in LNCaP cells through the activation of HK2 (hexokinase 2) and activation of the cardiac isoform of PFKFB2 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase). Activation of PKA (cAMP-dependent protein kinase) by androgen increased phosphorylation of CREB [CRE (cAMP-response element)-binding protein], which in turn bound to CRE on the promoter of the HK2 gene resulting in transcriptional activation of the HK2 gene. Up-regulation of PFKFB2 expression was mediated by the direct binding of ligand-activated androgen receptor to the PFKFB2 promoter. The activated PI3K (phosphoinositide 3-kinase)/Akt signalling pathway in LNCaP cells contributes to the phosphorylation of PFKFB2 at Ser466 and Ser483, resulting in the constitutive activation of PFK-2 (6-phosphofructo-2-kinase) activity. Glucose uptake and lipogenesis were severely blocked by knocking-down of PFKFB2 using siRNA (small interfering RNA) or by inhibition of PFK-2 activity with LY294002 treatment. Taken together, our results suggest that the induction of de novo lipid synthesis by androgen requires the transcriptional up-regulation of HK2 and PFKFB2, and phosphorylation of PFKFB2 generated by the PI3K/Akt signalling pathway to supply the source for lipogenesis from glucose in prostate cancer cells.

[1]  R. Schimke,et al.  Multiple forms of hexokinase in the rat: tissue distribution, age dependency, and properties. , 1965, Proceedings of the National Academy of Sciences of the United States of America.

[2]  P. Pedersen,et al.  High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[3]  P. Pedersen,et al.  Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. , 1981, The Journal of biological chemistry.

[4]  E. Schaftingen,et al.  A kinetic study of pyrophosphate: fructose-6-phosphate phosphotransferase from potato tubers. Application to a microassay of fructose 2,6-bisphosphate. , 1982, European journal of biochemistry.

[5]  P. Young,et al.  Reduced maximum capacity of glycolysis in brown adipose tissue of genetically obese, diabetic (db/db) mice and its restoration following treatment with a thermogenic β‐adrenoceptor agonist , 1984, FEBS letters.

[6]  B. Nelson,et al.  Evidence that transcription of the hexokinase gene is increased in a rapidly growing rat hepatoma. , 1985, Biochemical and biophysical research communications.

[7]  L. Boscá,et al.  Effect of glutamine on fructose 2,6-bisphosphate and on glucose metabolism in HeLa cells and in chick-embryo fibroblasts. , 1985, The Biochemical journal.

[8]  K. Kangawa,et al.  Phosphorylation of myocardial fructose-6-phosphate,2-kinase: fructose-2,6-bisphosphatase by cAMP-dependent protein kinase and protein kinase C. Activation by phosphorylation and amino acid sequences of the phosphorylation sites. , 1988, The Journal of biological chemistry.

[9]  M. Yamamoto.  [Glycolytic activity and fructose 2, 6-bisphosphate changes in rat brain during ischemia]. , 1990, No to shinkei = Brain and nerve.

[10]  H. Terada,et al.  Remarkably enhanced expression of the type II hexokinase in rat hepatoma cell line AH130 , 1991, FEBS letters.

[11]  D. Vertommen,et al.  The two forms of bovine heart 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase result from alternative splicing. , 1992, The Biochemical journal.

[12]  L. Hue,et al.  Mammalian 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: a bifunctional enzyme that controls glycolysis. , 1993, Progress in nucleic acid research and molecular biology.

[13]  M. Rider,et al.  Role of fructose 2,6-bisphosphate in the control of heart glycolysis. , 1993, The Journal of biological chemistry.

[14]  D. Mayer,et al.  Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages. , 1994, Biochimica et biophysica acta.

[15]  D. Wasserman,et al.  Rat skeletal muscle hexokinase II mRNA and activity are increased by a single bout of acute exercise. , 1994, The American journal of physiology.

[16]  Saroj P. Mathupala,et al.  Glucose Catabolism in Cancer Cells. , 1995, The Journal of Biological Chemistry.

[17]  I. Kurland,et al.  6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase: a metabolic signaling enzyme. , 1995, Annual review of biochemistry.

[18]  R. Printz,et al.  Identification and Characterization of Basal and Cyclic AMP Response Elements in the Promoter of the Rat Hexokinase II Gene* , 1996, The Journal of Biological Chemistry.

[19]  J. Swinnen,et al.  Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  D. Vertommen,et al.  Phosphorylation and Activation of Heart 6-Phosphofructo-2-kinase by Protein Kinase B and Other Protein Kinases of the Insulin Signaling Cascades* , 1997, The Journal of Biological Chemistry.

[21]  J. Swinnen,et al.  Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. , 1997, Cancer research.

[22]  W. Isaacs,et al.  Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. , 1998, Cancer research.

[23]  X. Estivill,et al.  Molecular cloning, expression, and chromosomal localization of a ubiquitously expressed human 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase gene (PFKFB3) , 1999, Cytogenetic and Genome Research.

[24]  D. Alessi,et al.  Heart 6-Phosphofructo-2-kinase Activation by Insulin Results from Ser-466 and Ser-483 Phosphorylation and Requires 3-Phosphoinositide-dependent Kinase-1, but Not Protein Kinase B* , 1999, The Journal of Biological Chemistry.

[25]  P. Dahia,et al.  PTEN, a unique tumor suppressor gene. , 2000, Endocrine-related cancer.

[26]  E. Pauwels,et al.  Positron-emission tomography with [18F]fluorodeoxyglucose , 2000, Journal of Cancer Research and Clinical Oncology.

[27]  R. Bartrons,et al.  PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate. , 2001, Trends in biochemical sciences.

[28]  N. Sadato,et al.  FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation , 2001, Nuclear medicine communications.

[29]  J. Swinnen,et al.  Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. , 2001, Molecular endocrinology.

[30]  H. Klocker,et al.  Androgen receptors in prostate cancer. , 2003, Endocrine-related cancer.

[31]  Min Gyu Lee,et al.  Glucose Metabolism in Cancer , 2003, Journal of Biological Chemistry.

[32]  J. Swinnen,et al.  Androgens, lipogenesis and prostate cancer , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[33]  H. Esumi,et al.  Hypoxia induces transcription of 6‐phosphofructo‐2‐kinase/fructose‐2,6‐biphosphatase‐4 gene via hypoxia‐inducible factor‐1α activation , 2004, FEBS letters.

[34]  C. Heinlein,et al.  Androgen receptor in prostate cancer. , 2004, Endocrine reviews.

[35]  Y. Erdi,et al.  Tumor Localization of 16β-18F-Fluoro-5α-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer , 2004 .

[36]  R. Bucala,et al.  Phosphorylation of the 6-Phosphofructo-2-Kinase/Fructose 2,6-Bisphosphatase/PFKFB3 Family of Glycolytic Regulators in Human Cancer , 2005, Clinical Cancer Research.

[37]  H. Esumi,et al.  Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors. , 2005, Biochimie.

[38]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[39]  S. Hong,et al.  Androgen‐dependent activation of human cytomegalovirus major immediate‐early promoter in prostate cancer cells , 2008, The Prostate.

[40]  Min-young Lee,et al.  KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cells. , 2009, The Biochemical journal.

[41]  H. Klocker,et al.  Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP‐dependent protein kinase A , 2010, International journal of cancer.

[42]  Y. Hirata,et al.  [Tumor localization]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.